New obesity drug HRS-5817 enters human safety testing

NCT ID NCT07238647

Ongoing Disease control Sponsor: Atridia Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety of a single dose of HRS-5817 in 40 obese adults aged 18-55. Participants receive either the drug or a placebo by injection. The study monitors side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5817
What this could lead to: If successful, this could lead to a new weight-loss drug that helps control obesity.
What could go wrong: This is a very early, small study focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Linear

Perth, Western Australia, 6027, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.